Install
Research & Evidence
Trial design, systematic reviews, medical statistics, and guideline updates.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Research & Evidence
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial
10+ hour, 20+ min ago (540+ words) Compass Pathways PLC (CMPS) shares were up more than 23% in Tuesday’s pre-market trade after the company announced that it had successfully achieved the primary endpoint in a Phase 3 clinical trial. Compass announced on Tuesday that its two Phase 3 trials have…...
HK inno.N's K-CAB Meets Primary Endpoints in U.S. Phase 3 Trial
5+ hour, 50+ min ago (472+ words) Heartburn and Acid Reflux Improved in 783 U.S. Patients Symptom-Free Days Rose Significantly Over Placebo After Four Weeks Added Erosive Esophagitis Analysis Wins ACG Presidential Award HK inno.N's (195940.KS) gastroesophageal reflux disease drug K-CAB improved heartburn and acid reflux symptoms in…...
AstraZeneca Efzimfotase Alfa Misses Primary Endpoint in HPP Trial
10+ hour, 10+ min ago (158+ words) Kathryn Dahir, MD, Director of the Programme for Metabolic Bone Disorders at Vanderbilt Health and lead investigator in the HICKORY trial, said: “These results from the HICKORY Phase III trial signal benefits across multiple clinically relevant endpoints and represent an…...
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
11+ hour, 29+ min ago (113+ words) Carroll County Mirror-Democrat SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to…...
Sebela Pharmaceuticals® Announces Submission of New Drug Application to FDA for Tegoprazan for the Treatment of Gastroesophageal Reflux Disease
6+ day, 11+ hour ago (192+ words) Jan 12, 2026, 08:00 ET GERD - A Significant Unmet Medical Need About the TRIUMpH Program The TRIUMpH program comprises two pivotal Phase 3 studies of tegoprazan in US patients with GERD, including both EE and NERD. The Phase 3 studies were conducted entirely in the…...
BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug
15+ hour, 19+ min ago (93+ words) (BBIO:NASDAQ) Seeking Alpha jittawit.21/iStock via Getty Images BridgeBio Pharma (BBIO) reported positive results from a late-stage clinical trial of its experimental drug encaleret, showing improvements in symptoms and bone health among patients with a rare genetic disorder that…...
Clinical Trials: More Than a Last Resort
14+ hour, 57+ min ago (213+ words) Targeted Oncology In an interview with Targeted Oncology, Krish Patel, MD, executive director of hematologic cancer research at Sarah Cannon Research Institute, discusses the benefits of clinical trialâbased care and what community oncologists should know when considering trials for…...
Grid-Shaped Radiation Beats Conventional Beams in Boosting CAR T Therapy for Brain Lymphoma
21+ hour, 56+ min ago (87+ words) A rat study shows that spatially fractionated minibeam radiation, unlike conventional radiotherapy, preserves the efficacy of CD19-directed CAR T cells and extends survival in primary CNS lymphoma. Subject of Research: Combining minibeam radiation therapy with CD19 CAR T cell therapy in…...
Weekly or Every-Three-Week Cisplatin? Trial Finds Similar Acute Toxicity Burden in p16-Negative Head and Neck Cancer
22+ hour, 19+ min ago (637+ words) The Phase II portion of the NRG-HN009 trial found that weekly cisplatin did not significantly reduce acute toxicity compared with every-three-week dosing in patients with p16-negative locally advanced head and neck cancer....
Tejas Patil: What Is Holding Back Cancer Clinical Trial Enrollment?
1+ day, 11+ hour ago (134+ words) Tejas Patil, Vice Head of Clinical Affairs and Thoracic Clinical Research Director in the Division of Oncology at the University of Colorado, Charles Jiang, Assistant Professor in Hematology and Oncology at UT Southwestern Medical Center, post on X: “A sobering look…...